{"id":600904,"date":"2026-06-24T14:39:32","date_gmt":"2026-06-24T14:39:32","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/600904\/vaccines-market-to-reach-6791-billion-by-2030-driven-by-expanding-immunization-programs-and-advancements-in-vaccine-technologies.html"},"modified":"2026-06-24T14:39:32","modified_gmt":"2026-06-24T14:39:32","slug":"vaccines-market-to-reach-6791-billion-by-2030-driven-by-expanding-immunization-programs-and-advancements-in-vaccine-technologies","status":"publish","type":"post","link":"https:\/\/www.pennsylvania-magazine.com\/news\/story\/600904\/vaccines-market-to-reach-6791-billion-by-2030-driven-by-expanding-immunization-programs-and-advancements-in-vaccine-technologies.html","title":{"rendered":"Vaccines Market to Reach $67.91 Billion by 2030, Driven by Expanding Immunization Programs and Advancements in Vaccine Technologies"},"content":{"rendered":"
\"Vaccines<\/a><\/div>\n
Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030<\/div>\n

According to MarketsandMarkets™,<\/strong> The global vaccines market<\/a><\/strong> (excluding COVID-19) is projected to grow from USD 47.65 billion in 2025 to USD 67.91 billion by 2030, at a CAGR of 7.3% during the forecast period. Market growth is being driven by increasing investments in vaccine research and development, the continuous introduction of innovative vaccine products, and expanding immunization coverage worldwide.<\/p>\n

Browse 437 market data Tables and 61 Figures spread through 449 Pages and in-depth TOC on <\/strong>“Vaccines Market “.<\/strong><\/p>\n

Download PDF Brochure: https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=1155<\/a><\/strong><\/p>\n

The rising prevalence of infectious diseases continues to underscore the importance of preventive healthcare, leading to increased demand for effective vaccination solutions. Governments and global health organizations are strengthening immunization initiatives, particularly in emerging economies, to improve vaccine accessibility and coverage. Additionally, advancements in vaccine technologies, including mRNA platforms and novel delivery systems, are enabling faster development and enhanced efficacy of vaccines.<\/p>\n

The growing pipeline of therapeutic vaccines and increased focus on personalized immunization strategies are expected to create new growth opportunities. Strong government support, funding, and public-private collaborations remain critical in sustaining long-term market expansion.<\/p>\n

Pneumococcal Vaccines Lead by Disease Indication<\/strong><\/p>\n

By disease indication, pneumococcal vaccines accounted for the largest share of the market in 2024. This dominance is attributed to the high global burden of pneumococcal infections, particularly among young children and elderly populations.<\/p>\n

Widespread inclusion of pneumococcal vaccines in national immunization programs, along with strong government initiatives and increasing awareness of pneumonia-related mortality, has significantly boosted demand. Continuous advancements in conjugate and polysaccharide vaccine technologies are further strengthening this segment’s growth.<\/p>\n

Pediatric Vaccines Segment to Witness Fastest Growth<\/strong><\/p>\n

By end user, pediatric vaccines are expected to register the fastest growth during the forecast period. This growth is driven by the high prevalence of infectious diseases among children and the inclusion of multiple vaccines in routine childhood immunization schedules.<\/p>\n

Global initiatives led by organizations such as WHO, UNICEF, and Gavi are playing a vital role in expanding vaccine access and coverage. Additionally, the introduction of combination vaccines that reduce the number of injections, along with increasing parental awareness about early immunization, is further accelerating demand.<\/p>\n

Request Sample Pages: https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=1155<\/a><\/strong><\/p>\n

North America Dominates the Global Market<\/strong><\/p>\n

North America held the largest share of the vaccines market in 2024, supported by advanced healthcare infrastructure, strong government immunization programs, and high adoption of innovative vaccine technologies such as mRNA and recombinant platforms.<\/p>\n

The region benefits from substantial R&D investments, favorable reimbursement frameworks, and widespread public awareness campaigns promoting vaccination. The presence of leading vaccine manufacturers and continued focus on pandemic preparedness further reinforce North America’s market leadership.<\/p>\n

Competitive Landscape<\/strong><\/p>\n

Key players in the vaccines market include Merck & Co., Inc. (US), GSK Plc (UK), Pfizer, Inc. (US), Sanofi (France), AstraZeneca (UK), Johnson & Johnson Services Inc. (US), Emergent (US), Mitsubishi Tanabe Pharma Corporation (Japan), Serum Institute of India Pvt. Ltd. (India), and CSL (Australia), among others.<\/p>\n

These companies are focusing on expanding their vaccine portfolios, investing in next-generation technologies, and strengthening global distribution networks to meet the rising demand for immunization.<\/p>\n

Related Reports:<\/strong><\/p>\n

Cancer Vaccines Market<\/a> – Global Forecast to 2032<\/strong><\/p>\n

Veterinary Vaccines Market<\/a> – Global Forecast to 2030<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> MarketsandMarkets\u2122 Research Private Ltd.<\/a>
Contact Person:<\/strong> Mr. Rohan Salgarkar
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18886006441
Address:<\/strong>1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City:<\/strong> Florida
State:<\/strong> Florida
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.marketsandmarkets.com\/Market-Reports\/vaccine-technologies-market-1155.html<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/600904"}],"collection":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/comments?post=600904"}],"version-history":[{"count":0,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/posts\/600904\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/media?parent=600904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/categories?post=600904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pennsylvania-magazine.com\/news\/wp-json\/wp\/v2\/tags?post=600904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}